← Back to headlines
Vanda Pharmaceuticals Receives EU Orphan Designation for Psoriasis Drug
Vanda Pharmaceuticals has been granted orphan designation by the European Commission for its drug imsidolimab, intended for the treatment of generalized pustular psoriasis. This designation aims to encourage the development of treatments for rare diseases.
24 Aug, 11:16 — 24 Aug, 11:49
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (19/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center2
Center (2)
morningstarinvesting-com
Right
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
morningstar20h ago
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - Morningstar
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission Morningstar
Read full article →investing-com21h ago
Vanda gets EU orphan designation for psoriasis drug imsidolimab
By Investing.com
Read full article →Coverage Timeline
First report: investing-com · 24 Aug, 11:16|Full coverage: 2 · 33m|Window: 33m
Left-leaningCenterRight-leaning
